• The global solar energy market is forecasted by Fortune Business Insights to rise from $3.33 billion in 2022 to over $20 billion by 2030
• Turbo Energy S.A. will be part of the explosive growth, as tech-infused photovoltaics become instrumental in more efficient use of solar energy
• Turbo Energy S.A. is a leader in the residential markets in Spain, offering a complete lineup of Li-ion batteries, inverters, software, and their turnkey product, Sunbox

The world is facing a critical juncture. Our dependence on fossil fuels has demonstrably contributed to climate change, necessitating a global shift towards cleaner, more sustainable energy sources. Solar energy, harnessed through photovoltaic (“PV”) technology, offers a promising solution. However, to truly unlock its potential and pave the way for a more sustainable future, advancements in technology are crucial.

The answer resides in the exciting world of tech-infused photovoltaics, the path towards widespread solar harvesting and energy management, and the potential role Turbo Energy (NASDAQ: TURB) can play in this revolution.

The Rise of Tech-Infused Photovoltaics:

Traditional PV panels have served as the workhorses of solar energy generation. However, limitations exist and have become increasingly clear in recent years. Efficiency rates, the percentage of sunlight converted to electricity, are often capped, and energy production can fluctuate based on weather conditions. Here’s where technology steps in.

Scientists are constantly innovating in materials science, creating next-generation products. Perovskite solar cells, for example, hold immense promise with the potential to surpass the efficiency limits of traditional silicon-based panels. Artificial Intelligence (“AI”) has percolated into nearly all walks of life today, including photovoltaics. AI, which Turbo Energy leverages, can optimize panel use, manage energy production and storage more efficiently.

AI dovetails with IoT (Internet of Things), where sensors in solar panels can provide real-time data on performance, enabling proactive maintenance and maximizing output. Lastly, integrating solar energy into “smart grids” allows for a more dynamic and interconnected energy ecosystem, enabling efficient distribution and balancing of power demands.

Cumulatively, these technological advancements are transforming photovoltaics, generating more electricity from the same amount of sunlight, and subsequently using it more efficiently. They will be a driving force in a global solar energy market forecast by Fortune Business Insights to rise from $3.33 billion in 2022 to over $20 billion by 2030.

TURB: the Road to Sustainable Energy

Turbo Energy S.A., which just came public in September, designs, develops and manufactures equipment for the generation, management, and storage of photovoltaic energy in Spain, Europe and internationally. Positioned at the intersection of technology and energy, the company is pioneering the path to sustainable distributed (power is produced close to where it is consumed) energy future that demands a multifaceted approach. 

Turbo Energy’s product portfolio includes lithium-ion (Li-ion) batteries, multiple models of inverters, software system, and its new all-in-one Sunbox that combines all the components necessary to operate and protect a PV installation.

The company is one of the leaders that introduced Li-ion batteries for photovoltaic energy storage in Spain. Primarily for the home energy storage market, the company’s batteries have capacities from 2.24 kWh to 5.1 kWh in 24 and 48 volts. In addition, its 48V / 5.1 kWh units are available in a dual battery system.

In communication with the inverter, Turbo Energy’s software monitors energy flows between the photovoltaic panels, household consumption, storage and an optional electric vehicle charging station. The software allows users to customize an automatic backup mode based on weather forecasts, or manually select which part of the battery will be reserved for possible power outages. It also allows the battery to be used in a peak shaving mode, which incorporates AI to trigger battery power when grid energy is most expensive, effectively reducing the amount of high-cost power drawn from the grid.

Not Just Energy. More Energy, Better Managed.

The future of energy is undoubtedly tech driven. PV has long been heralded for its potential and is the best understood sustainable energy by consumers. Yet, it has been critiqued for certain limitations, obstacles that companies like Turbo Energy are overcoming today. Advancements in photovoltaics offer a path towards a sustainable future powered by the sun. Companies like Turbo Energy S.A., with their focus on cleantech and energy solutions, have the potential to play a role in this revolution. As technology continues to evolve and solar energy becomes more efficient and cost-effective, we can expect a paradigm shift in how we generate, manage, and consume energy, paving the way for a cleaner and more sustainable future.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

• Sigyn Therapeutics CEO Jim Joyce reviewed the company’s pipeline of technologies, including ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM) to improve patient responses to various cancer therapies, and Sigyn Therapy(TM) to address drug resistant viral and bacterial infections, endotoxemia, and sepsis, a leading cause of hospital deaths in the United States
• The company created Sigyn Therapy(TM) to treat pathogen-associated disorders that are not addressed with drug therapies
• Sigyn Therapeutics is developing ChemoPrep(TM) and ImmunePrep(TM), to improve patient responses to chemotherapy and immunotherapeutic antibodies, respectively
• To reduce toxicity, the company designed ChemoPure(TM) to sweep off-target chemotherapy from the bloodstream before it is able to cause the death of healthy patient cells

Sigyn Therapeutics (OTCQB: SIGY), a San Diego-headquartered medical technology company that creates medical solutions to treat life-threatening conditions, took part in the recent Emerging Growth Conference, with CEO Jim Joyce giving a live online presentation and updating attendees on the company’s portfolio of technologies, including Sigyn Therapy(TM), ChemoPrep(TM), ChemoPure(TM), and ImmunePrep(TM), which have each been designed to overcome a current limitation in healthcare (https://ibn.fm/HSNBl).

“We have two classes of product candidates. The first are devices to treat pathogen-associated disorders that are beyond the reach of drugs, and then we have a series of devices designed to improve patient responses to cancer therapies. The convergence of medical devices to enhance cancer drug therapies has the potential to be a new product category,” introduced Mr. Joyce.

Sigyn Therapy(TM)

As it relates to pathogen-associated disorders, the company has advanced Sigyn Therapy(TM) from concept through product development and subsequently completed five invitro blood purification studies, which validated the ability of Sigyn Therapy(TM) to extract 12 different therapeutic targets from human blood plasma.  As a result of these study outcomes, Sigyn Therapy(TM) is a candidate to treat a wide range of pathogen-associated disorders that are not addressed with drug therapies. The company also completed animal studies at the University of Michigan and then collaborated with a leading dialysis organization to establish the treatment protocol, site locations, and principal investigators for first-in-human studies of Sigyn Therapy(TM).

As indicated by Mr. Joyce, “We believe Sigyn Therapy has an unprecedented capability to simultaneously clear deadly inflammatory mediators and pathogenic sources of life-threatening inflammation from human blood.”

Sigyn Therapeutics is preparing to initiate first in-human studies of Sigyn Therapy, having drafted an Investigational Device Exemption (“IDE”) for submission to the U.S. Food and Drug Administration (“FDA”). The study intends to demonstrate the safety of Sigyn Therapy(TM) in dialysis-dependent end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation. “As per our protocol, we plan to enroll a total of 12 to 15 ESRD patients at three site locations,” he conveyed.

Mr. Joyce went on to discuss the potential value of Sigyn Therapy to the dialysis industry as well as non-dialysis markets. Designed as a single-use disposable device that is deployable on dialysis machines, Sigyn Therapy could provide dialysis organizations such as Fresenius Medical Care and DaVita Inc., a strategy to improve the health of their current patient population as well as a potential pathway into non-dialysis markets.

Solutions to Improve Patient Response to Cancer Therapies

Sigyn Therapeutics is also developing devices to improve patient responses to chemotherapy and immunotherapeutic antibodies to treat cancer.

“Something you need to know – something you probably don’t know – is that both chemotherapy and immunotherapeutic antibodies are poorly delivered to their intended cancer targets,” explained Mr. Joyce. “In general, published reports would indicate that less than 2% of chemotherapy and immunotherapeutic antibodies are successfully delivered to their targets. So, consider that no more than $200 of a $10,000 drug dose is likely to provide patient benefit.  We are looking to overcome the delivery limitations of these drugs.”

Against this backdrop, Sigyn Therapeutics is focused on enhancing the performance of cancer drugs. “We have designed devices to optimize the delivery of chemotherapy and therapeutic antibodies. And we do this by extracting circulating decoys that sequester or interfere with the delivery of these drugs to intended cancer targets. Our clinical objective is straightforward: improve drug delivery, reduce toxicity, and extend patient life,” he continued.

The company has developed ChemoPrep and ImmunePrep, which are designed to enhance the delivery of chemotherapy and therapeutic antibodies, respectively. “ChemoPrep is administered prior to chemotherapy infusion to sweep tumor-derived exosomes and other drug blocking agents from the bloodstream prior to the subsequent administration of chemotherapy.”

To reduce toxicity, the company is developing ChemoPure to be administered after the delivery of chemotherapy to sweep off-target chemotherapy from the bloodstream before it is able to cause the death of healthy patient cells.

In discussing ImmunePrep, Mr. Joyce overviewed the immense opportunities in the therapeutics antibodies market, noting that immunotherapeutic antibodies represent nine of the top 15 selling cancer drugs and have been at the center of multi-billion-dollar mergers and acquisitions. “When we reference immunotherapeutic antibodies, I just want you to know this is inclusive of monoclonal antibodies, checkpoint inhibitors, and antibody drug conjugates. There are over 1000 antibodies right now being evaluated in human studies. However, there is no therapy that’s been proposed prior to ImmunePrep to address the drug decoys that inhibit the delivery of these drugs,” he continued.

Unlike ChemoPrep, ImmunePrep establishes a platform for therapeutic antibodies to be incorporated within medical devices to sweep drug decoys from the bloodstream that would intercept the delivery of the same therapeutic antibody when subsequently administered. The company believes this reverse decoy mechanism will increase the availability of infused antibodies to bind their intended therapeutic target.  Simultaneously, the ImmunePrep device is designed to extract intended cancer cells targets of the antibody from the bloodstream to provide further benefit without added drug toxicity.

Mr. Joyce also fielded questions, using this opportunity to compare the Sigyn Therapy with other blood purification technologies that treat pathogen-associated conditions as well as discuss the company’s potential revenue verticals, funding outlook, development timelines, and potential opportunities to collaborate with medical device and biopharmaceutical organizations.

To listen to the full presentation, please visit https://ibn.fm/7AuwX.

For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

• Longeveron recently released its full-year results for the period ended December 31, 2023, and provided a corporate update
• The update outlined the company’s plans to prioritize the development of Lomecel-B(TM) in Hypoplastic Left Heart Syndrome (“HLHS”), a rare, pediatric congenital heart condition characterized by an underdeveloped left side of the heart
• Longeveron plans to complete the enrollment in the ELPIS II trial for HLHS in 2024
• The company also reported that it is exploring opportunities to advance its Alzheimer’s disease program through potential partnerships or other sources of funding

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicine for life-threatening conditions with unmet medical needs, recently released its full-year results for the period ended December 31, 2023, and provided a corporate update (https://ibn.fm/iORBu). Results from multiple studies using Longeveron’s lead investigational therapeutic candidate, Lomecel-B(TM), were announced by the company last year.

“In 2023 we made significant strides advancing studies of our investigational product, Lomecel-B(TM), in Hypoplastic Left Heart Syndrome (“HLHS”) and Alzheimer’s disease, with long-term survival data from ELPIS I trial presented at the American Heart Association (‘AHA’) annual meeting and clinically meaningful results announced from our Phase 2a CLEAR MIND clinical trial of Lomecel-B(TM) in the treatment of mild Alzheimer’s disease,” said Longeveron CEO Wa’el Hashad.

The ELPIS I trial was an open-label Phase 1 study designed to investigate the safety and potential efficacy of the intramyocardial injection of Lomecel-B(TM) administered to 10 infants with HLHS during the Glenn procedure, the second of three open-heart surgeries performed to correct HLHS, at about 4-5 months of age. (HLHS is a congenital condition characterized by the underdevelopment of the left side of the heart.) The final results from the study, announced in September 2021, showed that the study met its primary safety endpoint and that all patients were alive, transplant-free, and maintained their expected rate of growth one year after treatment (https://ibn.fm/nTsZs).

Nonetheless, after ELPIS I came to its planned end, investigators elected to extend the follow-up of the 10 infants for a total period of five years. It is the data from this ongoing extended long-term follow-up that the company presented as a poster at the 2023 annual AHA meeting. The company also summarized this data in its recent corporate update, noting that children in the ELPIS I trial had 100% transplant-free survival up to five years of age after receiving Lomecel-B(TM) compared to about 20% mortality rate observed from historical control data. This data, the update continued, reinforces the potential survival benefit of Lomecel-B(TM) for patients with HLHS.

The update also emphasized Longeveron’s prioritization of the development of Lomecel-B(TM) in HLHS. “For 2024 our main strategic priority will be focused on our lead clinical program in HLHS, our most important near-term value driver. Accordingly, we made the strategic decision to discontinue our Phase 2 clinical program in Aging-related Frailty in Japan,” explained Hashad.

The company is expecting to complete enrollment in the ELPIS II trial, a Phase 2 controlled clinical trial, in the fourth quarter of calendar 2024. (The company announced in August last year that it had surpassed 50% enrollment threshold) (https://ibn.fm/eBxKN). To achieve this target, Longeveron plans to implement additional measures that the company’s management outlined during the conference call that accompanied the release of the financial results (https://ibn.fm/vVij1).

For instance, Longeveron is in the process of activating new sites to add to its existing seven sites. Additionally, the company is working with advocacy groups to increase awareness among patients and is planning to hold an investigator meeting during which the company intends to take additional measure with the goal of expediting study enrollment.

“We are also exploring opportunities to advance our Alzheimer’s disease program through potential partnerships or other sources of funding. These steps will allow us to focus our available resources on completing enrollment in our follow-on ELPIS II study in 2024. HLHS patients are in critical need of new therapeutic options to improve outcomes in this rare and life-threatening indication,” Hashad continued.

Longeveron’s focus on its Alzheimer’s disease program comes on the back of positive results from the Phase 2a CLEAR MIND trial of Lomecel-B(TM) for the treatment of mild Alzheimer’s disease. According to the corporate update, the study met its primary safety and secondary endpoints. These results, Longeveron stated, support the therapeutic potential of Lomecel-B(TM) in treating mild Alzheimer’s disease and provide evidence-based support for potential further clinical development.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

For more information, visit the company’s website at www.Longeveron.com.

NOTE TO INVESTORS: The latest news and updates relating to LGVN are available in the company’s newsroom at http://ibn.fm/LGVN

• The cannabinoid market value in 2023 was $22.23 billion and is expected to grow at a CAGR of 15.3%, resulting in an estimated market value of $60.36 billion
• The global mass spectrometry market will reach $6.77 billion in 2024 and is expected to grow at a CAGR of 6.25%, reaching $9.17 billion by 2029.
• Astrotech and subsidiary AgLAB Inc. are using mass spectrometry to boost the profitable yield of hemp and cannabis production

The United States has seen a rising awareness of the health and therapeutic benefits of cannabinoids, prompting an expected market increase of 15.3%, from $22.23 billion in 2023 to an anticipated $60.36 billion by 2030 (https://ibn.fm/xyDpO). Focused on optimizing and improving higher yields, Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, and its wholly-owned subsidiary AgLAB Inc., have developed a mass spectrometer designed for use in the hemp and cannabis market.

During the process of converting cannabis biomass into distillate, valuable cannabinoids are typically lost resulting in reduced profits. AgLAB’s Maximum Value Processing (“MVP”) Method that uses the powerful AgLAB-1000-D2 mass spectrometer to test and to accurately configure the distillation system for optimal efficiency.

The AgLAB MVP mass spectrometer and its rugged design is built to withstand the demands of the factory floor. The AgLAB-1000-D2 model offers real-time potency tests during each distillation batch cycle.  During the distillation process up to 20 tests per hour can be achieved providing almost instant, real-time results which is used to adjust parameters, such as temperature, feed rate, and vacuum, to optimize potency and increase yields for each batch. Currently testing results can take days to complete resulting in little intelligence towards processing efficiency.

“This product and method fill a void by providing an easy and accurate real-time analysis that is used to make the right adjustments and improve the yields,” an AgLAB employee, was quoted as saying in a press release about AgLAB’s 1000 series (https://ibn.fm/kD3IM).

AgLAB’s method has been extensively tested and has shown impressive results, including increased revenue and profit margins. Internal studies have shown an average revenue improvement of $5,000 per 200 kg of crude, with a 24% profit increase. Furthermore, a case study revealed a 32.9% increase in distillate mass, translating to significant weekly and annual revenue gains.

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

• Video streaming is expected to reach a market size of $279.5 million in 2024 and grow to $1.3 billion by 2034 due to the demand for live-streamed content and technology advancements
• Immersive content is in high demand – blending lifestyle content with entertainment elements, often through apps supporting Video-On-Demand content and traditional broadcast television
• Bravo’s acquisition of Streaming TVee’s assets further the company’s goal of advancing its video streaming and entertainment ventures with a beta launch of its TVee NOW(TM) streaming service in Q1 2024

The video streaming market is expected to keep growing in the coming years. It is estimated to grow from $279.5 million in 2024 to $1.3 billion by 2034, growing at a CAGR of 16.4%. The market’s substantial growth is due to an increased demand for live-streaming content and technological advancements that propel the expansion of the market (https://ibn.fm/Bopwf). Bravo Multinational (OTC: BRVO), a company focused on exploring opportunities in the entertainment, hospitality, and technology sectors to generate long-term value for its shareholders through high-growth business ventures, is focused on advancing video streaming and its entertainment ventures.

The key to capturing an audience’s attention in entertainment lies in delivering outstanding content and immersive experiences that seamlessly blend lifestyle and entertainment elements. Content creators can forge deeper connections with audiences and leave lasting impressions by using their expertise across various domains, including television, film, music production, live events, immersive attractions, culinary experiences, retail products, and gaming.

One of the fundamental aspects of connecting lifestyle and entertainment is understanding the pulse of the audience. Content creators must delve into their target demographic’s preferences, aspirations, and cultural nuances to craft experiences that resonate on a personal level. Whether through compelling storytelling, innovative visual techniques, or interactive elements, the goal is to transport audiences into a world where they feel fully immersed and engaged.

Television and film serve as powerful mediums for storytelling, offering a canvas for creators to explore a variety of narratives and perspectives. By producing high-quality content that reflects the richness of human experiences, filmmakers can evoke emotions, spark conversations, and inspire change. From gripping dramas to light-hearted comedies, each genre presents an opportunity to delve into different facets of lifestyle while keeping entertainment at the forefront.

Music production and behind-the-scenes content add another dimension to the immersive experience. Whether creating original soundtracks for films, curating playlists for live events, or producing albums that capture the essence of a particular lifestyle, music can evoke emotions and set the tone for memorable moments. By integrating music seamlessly into various entertainment offerings, creators can amplify the overall experience and forge deeper connections with their audience.

In February 2024, Bravo finalized a deal to acquire Streaming TVEE Inc.’s assets, allowing it to establish its flagship offering – TVee NOW(TM). The acquired assets provide the company with the technology and foundation to offer streaming services, including Video-On-Demand (“VOD”) and traditional broadcast television through a joint venture partner.

In the acquisition, Bravo obtained exclusive rights, image and likeness, label waivers, and exploitation rights for streaming 117 high-definition music and comedy performances – offering director’s cuts and multiple camera perspectives. The original content offering will allow Bravo to recreate shows in diverse formats, showcasing concert films in a new full-feature format.

Bravo’s service is set for beta launch in Q1 2024. It will be accessible across various devices, with dedicated apps on platforms like Roku, Apple, and Google Play stores. The offering only reinforces the company’s commitment to innovation and audience accessibility.

For more information, visit the company’s website at www.BravoMultinationalInc.com.

NOTE TO INVESTORS: The latest news and updates relating to BRVO are available in the company’s newsroom at https://ibn.fm/BRVO

• Demand for photovoltaic energy storage systems in the EU is growing, driven by increased demand for energy security, renewable energy sources, and grid stability
• TURB strongly positioned with patented Sunbox – an AI-powered solution for home and business photovoltaic systems
• Sunbox leverages AI-powered algorithms to optimize energy usage, maximize efficiency, and protect against price shocks
• Market size for solar energy storage batteries projected to grow from $4.40 billion in 2023 to $20.01 billion by 2030 at a CAGR of 24.2%

Demand for photovoltaic energy storage systems in the European Union is growing, driven by environmental concerns and the goal of reducing dependence on fossil fuels (https://ibn.fm/dXFtt). The adoption of solar power systems combined with battery storage is driving the surge with an emphasis on energy security, integration of renewable energy sources, and enhanced grid stability.

Turbo Energy (NASDAQ: TURB), a photovoltaic energy company based in Spain, is strongly positioned to capitalize on increased demand with its patented Sunbox – an AI-powered solution for home and commercial photovoltaic installations.

Following the recent acquisition of an international patent, Turbo Energy is now strategically determining the countries for registration. “The result will be a unique energy storage solution that we believe will provide Turbo a leading position in this industry worldwide and help pave the way towards a more sustainable and energy-efficient future,” stated Turbo as they received their Spanish patent (https://ibn.fm/LqEcR).

Sunbox helps EU policymakers meet environmental goals while incentivizing consumers through lowered energy costs, maximized efficiency, and price shock protection. The system provides a comprehensive and intelligent energy management solution, utilizing AI algorithms to optimize energy usage while ensuring a reliable power supply. Additionally, the integration of an electric vehicle charger enables seamless charging at home and increased reliability on the road.

“It is the result of years of work on power inverters’ electronics with the aim of making them more useful for the end consumer,” said Pablo de la Cuadra, Director of Development at TURB.

The projected market size for solar energy storage batteries is anticipated to expand from $4.40 billion in 2023 to $20.01 billion by 2030 at a CAGR of 24.2% over the forecast period (https://ibn.fm/ulfj9). As an industry pioneer, TURB offers next-generation solar energy batteries that leverage proprietary software, offering a competitive advantage in the growing sector. With a focus on the home energy storage market, TURB’s batteries boast capacities ranging from 2.24 kWh to 5.1 kWh in 24 and 48 volts, with the latter option available in a dual battery system.

Turbo Energy was incorporated in 2013 and operates as a subsidiary of Umbrella Solar Investment S.A. in Valencia, Spain. Led by CEO Mariano Soria, the company’s management team leverages decades of experience in renewable energy technology, finance, and sales to drive the company’s strategic vision forward in the growing energy storage market industry.

For more information, visit the company’s website at www.Turbo-e.com.

NOTE TO INVESTORS: The latest news and updates relating to TURB are available in the company’s newsroom at https://ibn.fm/TURB

Astiva Health Inc. is pioneering transformative healthcare for seniors, with a focus on enhancing mobility and promoting independence. This innovative approach places a strong emphasis on seniors as active participants in their healthcare journey, representing a shift towards a more interactive and preventive model of care.

Embracing Active Participation

Central to Astiva Health’s mission is empowering seniors to engage actively in their healthcare decisions, supporting their flourishing in later years. The CDC highlights physical activity’s crucial role in preventing chronic diseases among seniors, noting that regular physical activity can significantly reduce health risks associated with inactivity (CDC, 2020).

Tailored Exercise Programs for Active Participants

Astiva Health is committed to empowering seniors through customized exercise programs that cater to their unique needs and health goals. The organization facilitates easy access to a variety of activities, including gyms, yoga, and water aerobics. Next year, Astiva will introduce new exercise benefits, enabling members to access additional facilities, fostering an environment where seniors can actively engage in their wellness journey.

Nutritional Support and Healthy Lifestyle Choices

Astiva Health places a strong emphasis on nutritional support, offering a top-of-the-market grocery benefit of currently $100 per month to encourage seniors to choose healthy foods. This initiative ensures that grocery benefits are accessible at local markets where seniors commonly shop, making it easier for them to incorporate nutritious foods into their diet. This approach has seen nearly 100% usage by Astiva’s members, significantly simplifying the process of maintaining a healthy diet compared to other programs that may appear beneficial but are difficult to utilize.

Accessible Transportation: Empowering Mobility

To overcome mobility challenges and encourage active participation in community life, Astiva Health provides accessible transportation solutions. This initiative helps seniors maintain an active social life, access healthcare appointments, and engage in community events, directly combating isolation and promoting inclusivity.

Conclusion

Astiva Health Inc. is redefining senior healthcare by fostering an environment where seniors are recognized as active participants in their health management. Through tailored exercise programs, substantial grocery benefits encouraging healthy eating, and accessible transportation, Astiva Health empowers seniors to lead more active, healthy, and independent lives. As the global population ages, Astiva’s proactive and participatory healthcare solutions become increasingly essential for ensuring seniors can thrive in their golden years.

For more about Astiva Health’s innovative approach to senior healthcare, visit AstivaHealth.com. Astiva is dedicated to offering innovative, culturally responsive Medicare Advantage options tailored to the active lifestyles of modern seniors.

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Clene’s recently released 2023 financial and operational updates highlight the company’s developments for the treatment of amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis
• CNM-Au8(R) functions as a neuroprotective and remyelinating therapy in neurodegenerative diseases
• Recent data from the randomized, double-blind, placebo-controlled HEALEY-ALS Platform Trial and its open-label extension, reported by Clene in December 2023, revealed encouraging outcomes on survival and delayed clinical worsening
• Clene recently provided perspectives on its achievements and the development path for CNM-Au8(R) during its participation in the 36th Annual ROTH Conference, which was held March 18-19, 2024

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently announced its 2023 operational highlights for its lead candidate, along with future goals. Clene’s lead candidate, CNM-Au8(R), is a gold nanocrystal suspension that has emerged as a promising candidate for the treatment of both ALS and MS (https://ibn.fm/bzDSB).

The unique catalytic mechanism of CNM-Au8 is believed to function as a neuroprotective and remyelinating therapy in neurodegenerative diseases by: (1) driving, supporting, and maintaining beneficial metabolic and energetic cellular reactions within diseased, stressed, or damaged cells, (2) directly catalyzing the reduction of harmful reactive oxygen species (“ROS”), and (3) promoting protein homeostasis through activation of the heat shock factor-1 pathway. This pathway is known to mitigate the cytotoxic effects of misfolded and denatured proteins, which are prevalent in neurodegenerative diseases.

Clene, in collaboration with Columbia University and Synapticure, secured a substantial grant from the NIH in October 2023 to offer an Expanded Access Program (“EAP”) to people living with ALS who do not qualify for clinical trials. Additionally, recent data from the HEALEY-ALS Platform Trial and its open-label extension, reported by Clene in December 2023, revealed encouraging outcomes: CNM-Au8 30 mg treatment was associated with a substantial decrease in the long-term risk of all-cause mortality compared to placebo, a result corroborated by a notable reduction in a plasma NfL levels. Survival benefit with CNM-Au8 treatment has now been reported as a result of the open label extension of the RESCUE-ALS Phase 2 Trial, the HEALEY-ALS platform trial Regimen C, its open-label extension, and in propensity-matched control analyses of two EAPs in ALS.

Despite the FDA’s decision in late 2023 against allowing Clene to move forward with an accelerated approval pathway based on initial biomarker data, Clene is diligently preparing supplemental data to provide additional supportive biomarker, survival, and mechanistic data, to advance discussions for accelerated approval and a new drug application (“NDA”) in 2024.

CNM-Au8’s therapeutic potential extends to MS, as indicated by Clene’s January 2024 report on substantial clinical and functional improvements observed in the long-term VISIONARY-MS trial, including sustained enhancements in vision and cognition over 35 months, alongside a favorable safety profile. These advancements align with recent publications explaining CNM-Au8’s mechanism of action and brain target engagement, further establishing its credibility as a therapeutic agent.

Rob Etherington, President and CEO of Clene, said, the company will continue to advance regulatory discussions with FDA this year, talks that will include new data on biomarkers, as well as additional clinical function and survival data in people living with ALS. “Having held our initial discussion with the FDA in the fourth quarter of last year, we have a clear understanding of the additional data required to support an accelerated approval pathway filing for CNM-Au8,” Etherington explained. “We believe that we can provide additional supportive evidence to advance discussions with the FDA with the potential to file an NDA later this year.”

In addition to Clene’s updates, the company recently participated in the 36th Annual ROTH Conference, which was held March 18-19, 2024. The conference was held at The Ritz Carlton Laguna Niguel in Dana Point, California. A webcast of Clene’s presentation is available in the “Events” section of the Clene website.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Lexaria, a global innovator in drug delivery platforms, recently hired a Contract Research Organization to perform their second GLP-1 human pilot study which will test a dissolvable DehydraTECH-GLP-1 oral dose formulation
• The announcement follows Lexaria’s WEIGHT-A24-1 animal study announcement examining diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and cannabidiol alone and in combination
• The move aligns with the company’s resolve to focus on their ability to enhance the delivery of GLP-1 diabetes and obesity drugs

At the beginning of the year, Lexaria Bioscience (NASDAQ: LEXX), a global innovator for enhanced drug delivery platforms, announced its intention to double down on GLP-1 clinical studies for the 2024 calendar year. This followed a successful, active year of R&D in 2023, which saw impressive results from its patented DehydraTECH(TM) technology for the improved delivery of GLP-1 agonists (glucagon-like peptide 1) used to treat type 2 diabetes and weight loss. According to Chris Bunka, the company’s CEO, these initial results fueled the management’s optimism in this new direction, emphasizing its superior pharmacokinetics and safety/efficacy performance of GLP-1 drugs when formulated with the technology.

“Given the overwhelming interest in the GLP-1 sector, this will be a main focus. We are not at this time planning additional 2024 research in the antiviral, nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka (https://ibn.fm/c3UuV).

In early March, Lexaria announced a 12-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol alone and in combination. The study, which will have 12 study arms, will involve a total rat population of 72 animals, with over 1,500 blood plasma samples collected over the duration of the study. Lexaria looks to build on the success of previous animal studies, which demonstrated, through brain tissue examination, that DehydraTECH can enable higher levels of drug delivery across the blood-brain-barrier and directly into the brain tissue (https://ibn.fm/N33Kc).

Everything is on track with this and other studies, with Lexaria hiring a contract research organization (“CRO”) to perform the second DehydraTECH-powered GLP-1 human pilot study. This randomized, crossover, placebo-controlled investigation will compare three dose formulations, each at a 7 mg semaglutide dose. So far, the manufacturing of the test articles is expected to be completed within 30 days, although Independent Review Board approval will be required before the study commences (https://ibn.fm/Vu8g6).

“DehydraTECH has previously shown an ability to improve the delivery of certain drugs destined for the bloodstream through the buccal/sublingual tissues of the mouth and throat,” noted Mr. Bunka. “If this new study is successful in demonstrating efficacy and safety, the potential for a new era in GLP-1 delivery without the need for painful injections or stomach-upsetting tablets could be within reach,” he added.

These milestones highlight Lexaria’s confidence in its DehydraTECH technology for enhancing drug delivery, and its understanding of its potential in the GLP-1 industry.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• MedCana adds to portfolio with strategic acquisition of two cannabis companies
• First acquisition represents “leap forward” in SFWJ’s commitment to innovation, excellence within the cannabis sector
• Second company holds key production, processing and exportation licenses that will strengthen MedCana’s operational chain

Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is growing its footprint in the cannabis space through savvy acquisitions. In the past few months, MedCana, a leading holding company in the cannabis industry, has announced two new acquisitions as the company keeps its eye on making strategic additions to its portfolio.

Last month, the company announced that it was in the final stages of negotiations to acquire its sixth cannabis company in Colombia (https://ibn.fm/6fAIH). This strategic acquisition is extremely significant because the targeted company holds a unique cannabis genetics license, which MedCana believes will revolutionize its potential to create and register unique cannabis genetic varieties for production and commercialization.

“The addition of this new company to MedCana’s portfolio represents a significant leap forward in our commitment to innovation and excellence within the cannabis sector,” said MedCana CEO Jose Gabriel Diaz. “By integrating this company’s cutting-edge genetics capabilities, MedCana will be poised to develop proprietary cannabis strains, enhancing the diversity and quality of our product offerings to meet the evolving needs of consumers and medical patients alike.”

Earlier in March, MedCana completed the previously announced acquisition plus the acquisition of a second company, bringing the number of companies in MedCana’s portfolio to nine (https://ibn.fm/PZmxC). The second company holds key production, processing and exportation licenses that will strengthen MedCana’s operational chain, supporting a seamless integration of supply from cultivation through to global distribution and ensuring the company’s position as a fully self-sufficient entity in the cannabis market.

“These acquisitions represent a monumental step towards our vision of becoming a world-leading integrated cannabis company,” said Diaz. “With seven cannabis-producing companies, one agriculture technology and infrastructure company, and one software company under our belt, MedCana is exceptionally positioned to innovate, produce and deliver high-quality cannabis products globally.”

MedCana is committed to developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. These recent acquisitions reflect the company’s focus on scientific advancements and sustainable practices as it works to achieve the broader goal of leading the cannabis industry through strategic growth and pioneering research. The company is excited about the future prospects these new assets bring to its operations and the vast opportunities for innovation they unlock.

Software Effective Solutions/MedCana is a holding company focused on developing companies in the agricultural technology and cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth of its holdings.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ